Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity.
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …

Importance Small cell lung cancer (SCLC) is an aggressive disease that is characterized by
rapid growth and the early development of metastases. Patients typically respond to initial …

Importance Programmed cell death ligand 1 inhibitors combined with chemotherapy has
changed the approach to first-line treatment in patients with extensive-stage small cell lung …

Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer. Although SCLC is
characterised by rapid responses to chemotherapy (ChT) and sensitivity to radiotherapy …

Background Most patients with small-cell lung cancer (SCLC) have extensive-stage disease
at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated …

Currently, chemotherapy remains the standard treatment for first-and second-line
management of small cell lung cancer (SCLC). Immunotherapy has made progress in the …

Immune-checkpoint inhibitors (ICIs) are approved in the first-line and third-line settings for
patients with extensive-stage or relapsed small-cell lung cancer (SCLC), respectively. In the …

Extensive-stage small-cell lung cancer is a therapeutically challenging disease. After more
than two decades without clinical progress, the addition of programmed cell death protein 1 …

Purpose The safety and efficacy of pembrolizumab, a humanized monoclonal antibody
against programmed death 1 (PD-1), were assessed in patients with programmed death …

Small-cell lung cancer (SCLC) is an aggressive malignancy associated with a poor
prognosis. First-line treatment has remained unchanged for decades, and a paucity of …